TMEV as a Vaccine Candidate
Author Information
Author(s): Pavelko Kevin D., Girtman Megan A., Mitsunaga Yoshihiro, Mendez-Fernandez Yanice V., Bell Michael P., Hansen Michael J., Allen Kathleen S., Rodriguez Moses, Pease Larry R.
Primary Institution: Mayo Clinic, Rochester, Minnesota, United States of America
Hypothesis
Can Theiler's murine encephalomyelitis virus (TMEV) be modified to serve as an effective T-cell vaccine for cancer immunotherapy?
Conclusion
The modified TMEV vaccine can induce strong cytotoxic T-cell responses and delay tumor growth in vaccinated animals.
Supporting Evidence
- The modified TMEV virus can generate CD8+ cytotoxic T-cell responses.
- TMEV-L/OVA vaccination leads to significant tumor growth delay.
- Vaccination with TMEV-L/OVA induces robust immune responses against introduced antigens.
Takeaway
Researchers are testing a virus that can help the body fight cancer by training immune cells to attack tumors.
Methodology
The study involved modifying the TMEV virus to include specific T-cell epitopes and testing its ability to induce immune responses in mice.
Potential Biases
Potential bias due to the use of animal models that may not fully replicate human responses.
Limitations
The study did not assess the long-term effects of the vaccine or its efficacy in human subjects.
Participant Demographics
C57BL/6 and other mouse strains were used in the experiments.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website